Inhibition of Alprazolam and Desipramine Hydroxylation In Vitro by Paroxetine and Fluvoxamine
- 1 April 1995
- journal article
- research article
- Published by Wolters Kluwer Health in Journal of Clinical Psychopharmacology
- Vol. 15 (2), 125-131
- https://doi.org/10.1097/00004714-199504000-00008
Abstract
In vitro preparations of human liver microsomes were used to study the inhibiting effects of two selective serotonin reuptake inhibitor (SSRI) antidepressants, paroxetine and fluvoxamine, on metabolism via hydroxylation of alprazolam and of desipramine. These reactions are mediated by Cytochromes P450-3A4 and P450-2D6, respectively. Paroxetine was a highly potent inhibitor of desipramine hydroxylation; the inhibition constant (Ki) value of 2.0 microM indicated greater inhibiting potency than fluoxetine or norfluoxetine. The in vitro data predicted in vivo impairment of desipramine clearance by coadministration of paroxetine which was in the same range as observed in a clinical study. Fluvoxamine, by contrast, was a much weaker inhibitor of desipramine hydroxylation, having a Ki value (16.6 microM) similar to those of sertraline and desmethylsertraline. For hydroxylation of alprazolam, paroxetine was a relatively weak inhibitor, approximately comparable to fluoxetine, whereas fluvoxamine showed inhibiting capacity similar to that of norfluoxetine. The in vitro data predicted the degree of impairment of alprazolam clearance observed in vitro model can therefore provide clinically relevant data on prediction of potential drug interactions with SSRIs.Keywords
This publication has 37 references indexed in Scilit:
- In Vitro Prediction of the Terfenadine‐Ketoconazole Pharmacokinetic InteractionThe Journal of Clinical Pharmacology, 1994
- Increased trimipramine plasma levels during fluvoxamine comedicationEuropean Neuropsychopharmacology, 1994
- FluvoxamineCNS Drugs, 1994
- Clinical Pharmacokinetics of Selective Serotonin Reuptake InhibitorsClinical Pharmacokinetics, 1993
- Alprazolam Metabolism in vitro: Studies of Human, Monkey, Mouse, and Rat Liver MicrosomesPharmacology, 1993
- Tricyclic Antidepressant Plasma Levels after Fluoxetine AdditionNeuropsychobiology, 1992
- Extremely Slow Metabolism of Amitriptyline but Normal Metabolism of Imipramine and Desipramine in an Extensive Metabolizer of Sparteine, Debrisoquine, and MephenytoinTherapeutic Drug Monitoring, 1991
- ParoxetineDrugs, 1991
- Fluoxetine Drug-Drug InteractionsJournal of Clinical Psychopharmacology, 1990
- Prediction of diazepam disposition in the rat and man by a physiologically based pharmacokinetic modelJournal of Pharmacokinetics and Biopharmaceutics, 1983